Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 6/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23872325 | 0.85 | XPO1 (0.45) | XPO1 | |
| SCHEMBL24465048 | 0.80 | XPO1 (0.38) | XPO1 | |
| SCHEMBL18197785 | 0.78 | XPO1 (0.44) | XPO1 | |
| SCHEMBL17537351 | 0.76 | CYP1A2 (0.49) | XPO1GAACYP1A2CYP3A4ALOX15 | |
| SCHEMBL24465067 | 0.72 | XPO1 (0.64) | XPO1 | |
| SCHEMBL12704678 | 0.71 | XPO1 (0.48) | XPO1 | |
| SCHEMBL8124542 | 0.71 | XPO1 (0.41) | XPO1CYP1A2 | |
| SCHEMBL20880362 | 0.69 | XPO1 (0.54) | XPO1 | |
| SCHEMBL17817932 | 0.68 | XPO1 (0.64) | XPO1 | |
| SCHEMBL1592573 | 0.68 | XPO1 (0.45) | XPO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3567035-B1 | N-SUBSTITUTED 2,5-DIOXO-AZOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CANBAS CO LTD (JP) | 2022-06-01 | — | — | EP | disclosed |
| EP-3567035-A1 | N-SUBSTITUTED 2,5-DIOXO-AZOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Canbas Co. Ltd. (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3088397-B1 | COMPOUNDS THAT ABROGATE THE CELL CYCLE G2 CHECKPOINT FOR USE IN THE TREATMENT OF CANCER | CANBAS CO LTD (JP) | 2019-04-10 | — | — | EP | disclosed |